{
  "abstract": "Interleukin-6, a pleiotropic cytokine, initiates downstream signaling by binding to interleukin-6 receptor α (IL-6Rα) and glycoprotein 130 (GP130). Autoimmune uveitis, the most prevalent form of non-infectious uveitis, represents a serious sight-threatening ocular disorder. While corticosteroids remain the mainstay of treatment in clinical practice, their therapeutic utility is constrained by significant adverse effects. Emerging evidence highlights the pivotal role of IL-6 in autoimmune uveitis pathogenesis, particularly in promoting CD4+T cells differentiation into Type 17 helper T cells (Th17). In this study, we evaluated the therapeutic efficacy of a novel anti-IL-6Rα nanobody in experimental autoimmune uveitis (EAU) models. Peripheral blood mononuclear cells (PBMCs) from Vogt-Koyanagi-Harada (VKH) patients were used to further assess the translational relevance of the anti-IL-6Rα nanobody. Our results demonstrate that this nanobody not only suppressed Type 17 helper T cells but also Type 1 helper T cells (Th1). Furthermore, treatment with anti-IL-6Rα nanobody significantly reduced inflammatory mediators and ameliorated disease severity in murine models. In vitro studies using PBMCs from VKH patients revealed that the anti-IL-6Rα nanobody effectively suppressed both interferon-γ (IFN-γ) and IL-17 production. These findings collectively suggest that anti-IL-6Rα nanobody represents a promising therapeutic strategy for autoimmune uveitis.\n\nSupplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s10753-026-02540-4.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Ophthalmology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001 P.R. China",
    "Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001 China",
    "Bengbu Medical University, Bengbu, Anhui China",
    "Department of Ophthalmology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001 China"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Bochen Yao"
    },
    {
      "affs": [
        0
      ],
      "name": "Dali Tong"
    },
    {
      "affs": [
        1
      ],
      "name": "Jiaojiao Qian"
    },
    {
      "affs": [
        0
      ],
      "name": "Yuewei Peng"
    },
    {
      "affs": [
        0
      ],
      "name": "Zhouhuan Xi"
    },
    {
      "affs": [
        2
      ],
      "name": "Niannian Fan"
    },
    {
      "affs": [
        0
      ],
      "name": "Feiyu Jin"
    },
    {
      "affs": [
        0
      ],
      "name": "Can Deng"
    },
    {
      "affs": [
        1
      ],
      "name": "Bofeng Li"
    },
    {
      "affs": [
        0,
        3
      ],
      "name": "Kai Dong"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8ya97hxymsnra.bib",
  "cited_by": 0,
  "doi": "10.1007/s10753-026-02540-4",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13710577/",
  "id": "8ya97hxymsnra",
  "issns": [
    "0360-3997",
    "1573-2576"
  ],
  "landing_url": "https://doi.org/10.1007/s10753-026-02540-4",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research"
    ],
    [
      "openalex",
      "2731|Ocular Diseases and Behçet’s Syndrome"
    ]
  ],
  "openalex": "W7167583006",
  "pdf_url": null,
  "pmcid": "PMC13710577",
  "pmid": "42412316",
  "published": "2026-07-07",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/8ya97hxymsnra.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T12:21:31Z",
      "native_id": "PMC13710577",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s10753-026-02540-4"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2731|Ocular Diseases and Behçet’s Syndrome",
      "subfield": "general"
    }
  ],
  "title": "A Self-Developed IL-6Rα Nanobody Alleviates Experimental Autoimmune Uveitis by Inhibiting Th1 and Th17 Cells",
  "title_text": "A Self-Developed IL-6Rα Nanobody Alleviates Experimental Autoimmune Uveitis by Inhibiting Th1 and Th17 Cells",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T12:21:31Z",
  "url": "https://research.draconitic.com/paper/8ya97hxymsnra",
  "venue": "Inflammation",
  "versions": []
}